CATHY FERNANDEZ: Open Payments
NPI 1184262370 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,908 in 87 payments from 17 companies in 2025. Trend: 2023 $491 · 2024 $986 · 2025 $1,908
Food & beverage: $1,908
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 22 | $410 |
| ABBVIE INC. | 16 | $344 |
| UCB, Inc. | 9 | $267 |
| GENZYME CORPORATION | 8 | $244 |
| GlaxoSmithKline, LLC. | 7 | $153 |
| Novartis Pharmaceuticals Corporation | 4 | $102 |
| Mallinckrodt Hospital Products Inc. | 5 | $84 |
| Janssen Biotech, Inc. | 4 | $63 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $43 |
Products named: Bimzelx, KEVZARA, RINVOQ, KRYSTEXXA, BENLYSTA, SKYRIZI, OTEZLA, ACTHAR.
Industry payments across TX — which companies pay providers there.
